Table 1.
Summary of patient characteristics
| Lone AF | MVD+AF | Control group | p Value | |
| Number | 56 | 46 | 15 | |
| PAF | 30 | 10 | −1 | |
| CAF | 26 | 36 | −1 | |
| Cardiac surgery | IRAAF | MVR+IRAAF | MVR (7) | |
| MVR+CABG (1) | ||||
| CABG (6) | ||||
| AVR+CABG (2) | ||||
| Age (years) | 48 (13) | 64 (10) | 59 (7) | <0.05 lone v MVD+AF |
| <0.05 SR v lone AF | ||||
| NS SR v MVD+AF | ||||
| LVEF (%) | 60 (6) | 57 (16) | 55 (13) | NS |
| Left atrium (mm) | 43 (6) | 55 (11) | 44 (7) | 0.001 lone AF v MVD+AF |
| <0.001 SR v MVD+AF | ||||
| Calcium antagonists (all) | 8 (14%) | 6 (13%) | 3 (19%) | |
| Digitalis | 16 (29%) | 32 (69%) | 2 (13%) | |
| β Blocker | 41 (93%) | 45 (98%) | 10 (63%) | |
| Antiarrhythmic drugs | 22 (39%) | 6 (13%) | 0 | |
| ACE inhibitors | 23 (41%) | 43 (93%) | 9 (56%) | |
| Spironolactone | 1 (2%) | 8 (17%) | 0 |
Data are mean (SD) or number (%).
ACE, angiotensin converting enzyme; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CAF, chronic atrial fibrillation; IRAAF, intraoperative radiofrequency ablation of atrial fibrillation; LVEF, left ventricular ejection fraction; MVD, mitral valve disease; MVR, mitral valve repair or replacement; NS, not significant; PAF, paroxysmal atrial fibrillation; SR, sinus rhythm.